Evidence map›Paper›PMID 31396668›Full record

ReviewSkeletal radiology2020

Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Shivani Ahlawat, Jaishri O Blakeley, Shannon Langmead, Allan J Belzberg, Laura M Fayad

Abstract readReview
PubMed Publisher
In one paragraph

Review in Skeletal radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Review
  4. Article
  5. [Interpretation of the Expert Consensus for Full Course Management of Plexiform Neurofibroma (2025 Edition)].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026
    Article
  6. Article
  7. Cancer predisposition syndromes: an imaging review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Review
  8. Article
  9. Sacroiliac Joint Involvement: An Underreported Complication of NF1.American journal of medical genetics. Part A · 2026
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. [Plastic surgical treatment of neurofibromatosis type 1].Chirurgie (Heidelberg, Germany) · 2025
    Review
  17. Update on Cancer and Central Nervous System Tumor Surveillance in Pediatric NF2-, SMARCB1-, and LZTR1-Related Schwannomatosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shivani AhlawatThe Russell H. Morgan Department of Radiology & Radiological Science, The Johns Hopkins University School of Medicine, 601 North Caroline Street, JHOC 3rd Floor, Baltimore, MD, 21287, USA. sahlawa1@jhmi.edu.ORCID http://orcid.org/0000-0003-4437-5237
Jaishri O BlakeleyDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shannon LangmeadDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Allan J BelzbergDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Laura M FayadThe Russell H. Morgan Department of Radiology & Radiological Science, The Johns Hopkins University School of Medicine, 601 North Caroline Street, JHOC 3rd Floor, Baltimore, MD, 21287, USA.
Johns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN) are three clinically distinct tumor predisposition syndromes with a shared tendency to develop peripheral and central nervous system neoplasms. Disease expression and complications of NF1, NF2, and SWN are highly variable, necessitating a multidisciplinary approach to care in order to optimize outcomes. This review will discuss the imaging appearance of NF1, NF2, and SWN and highlight the important role that imaging plays in informing management decisions in people with tumors associated with these syndromes. Recent technological advances, including the role of both whole-body and localized imaging strategies, routine anatomic and advanced magnetic resonance (MR) imaging sequences such as diffusion-weighted imaging (DWI) with quantitative apparent diffusion coefficient (ADC) mapping, and metabolic imaging techniques (MR spectroscopy and positron emission testing) are discussed in the context of the diagnosis and management of people with NF1, NF2, and SWN based on the most up-to-date clinical imaging studies.

Indexed as

HumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyNeurilemmomaNeurofibromatosesNeurofibromatosis 1Neurofibromatosis 2Positron-Emission TomographySkin NeoplasmsApparent diffusion coefficient (ADC) valuesDiffusion-weighted imaging (DWI)Imaging biomarkersMagnetic resonance imaging (MRI)Malignant peripheral nerve sheath tumor (MPNST)Neurofibromatosis type 1 (NF1)Neurofibromatosis type 2 (NF2)Schwannomatosis (SWN)

Identifiers

PMID31396668
OpenAlexW2968247845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.